Ascletis Pharma launches fresh HKD 1.97 million buyback; cumulative repurchases reach 7.89 million shares

Bulletin Express06-11

Ascletis Pharma Inc. disclosed in its Next Day Return (11 June 2026) that it repurchased 200,000 ordinary shares on the Hong Kong Stock Exchange the same day. The shares were bought within a price range of HKD 9.63–10.11, translating into an average cost of HKD 9.83 per share and an aggregate consideration of HKD 1.97 million.

The repurchased stock will be cancelled, leaving the company’s share capital structure unchanged ahead of formal cancellation: • Issued shares (excluding treasury shares) remain at 1,061,370,845. • Treasury shares stand at 7,084,210, keeping total issued shares at 1,068,455,055.

Buy-back mandate utilisation • Ascletis received shareholder approval on 22 May 2025 to repurchase up to 96.28 million shares. • Including the latest transaction, 7.89 million shares have been bought back, equal to 0.82 % of the issued share base on the mandate date.

Regulatory timeline Under Hong Kong Listing Rule 10.06(3), the company is subject to a moratorium on issuing new shares or selling treasury shares until 11 July 2026—30 days after the most recent repurchase.

The company confirmed all repurchases were executed in compliance with Hong Kong Stock Exchange requirements and that no changes have been made to the explanatory statement lodged on 29 April 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166873089?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 18:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166873089","market":"hk","top_or_hot":-1,"title":"Ascletis Pharma launches fresh HKD 1.97 million buyback; cumulative repurchases reach 7.89 million shares","media":"Bulletin Express","content":"<p>Ascletis Pharma Inc. disclosed in its Next Day Return (11 June 2026) that it repurchased 200,000 ordinary shares on the Hong Kong Stock Exchange the same day. The shares were bought within a price range of HKD 9.63–10.11, translating into an average cost of HKD 9.83 per share and an aggregate consideration of HKD 1.97 million.</p>\n<p>The repurchased stock will be cancelled, leaving the company’s share capital structure unchanged ahead of formal cancellation:  \n• Issued shares (excluding treasury shares) remain at 1,061,370,845.  \n• Treasury shares stand at 7,084,210, keeping total issued shares at 1,068,455,055.</p>\n<p>Buy-back mandate utilisation  \n• Ascletis received shareholder approval on 22 May 2025 to repurchase up to 96.28 million shares.  \n• Including the latest transaction, 7.89 million shares have been bought back, equal to 0.82 % of the issued share base on the mandate date.</p>\n<p>Regulatory timeline  \nUnder Hong Kong Listing Rule 10.06(3), the company is subject to a moratorium on issuing new shares or selling treasury shares until 11 July 2026—30 days after the most recent repurchase.</p>\n<p>The company confirmed all repurchases were executed in compliance with Hong Kong Stock Exchange requirements and that no changes have been made to the explanatory statement lodged on 29 April 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma launches fresh HKD 1.97 million buyback; cumulative repurchases reach 7.89 million shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma launches fresh HKD 1.97 million buyback; cumulative repurchases reach 7.89 million shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-11 18:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascletis Pharma Inc. disclosed in its Next Day Return (11 June 2026) that it repurchased 200,000 ordinary shares on the Hong Kong Stock Exchange the same day. The shares were bought within a price range of HKD 9.63–10.11, translating into an average cost of HKD 9.83 per share and an aggregate consideration of HKD 1.97 million.</p>\n<p>The repurchased stock will be cancelled, leaving the company’s share capital structure unchanged ahead of formal cancellation:  \n• Issued shares (excluding treasury shares) remain at 1,061,370,845.  \n• Treasury shares stand at 7,084,210, keeping total issued shares at 1,068,455,055.</p>\n<p>Buy-back mandate utilisation  \n• Ascletis received shareholder approval on 22 May 2025 to repurchase up to 96.28 million shares.  \n• Including the latest transaction, 7.89 million shares have been bought back, equal to 0.82 % of the issued share base on the mandate date.</p>\n<p>Regulatory timeline  \nUnder Hong Kong Listing Rule 10.06(3), the company is subject to a moratorium on issuing new shares or selling treasury shares until 11 July 2026—30 days after the most recent repurchase.</p>\n<p>The company confirmed all repurchases were executed in compliance with Hong Kong Stock Exchange requirements and that no changes have been made to the explanatory statement lodged on 29 April 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1166873089","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166873089","pubTimestamp":1781174534,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascletis Pharma Inc. disclosed in its Next Day Return (11 June 2026) that it repurchased 200,000 ordinary shares on the Hong Kong Stock Exchange the same day. The shares were bought within a price...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B"},"translate_title":"歌礼制药新推197万港元回购；累计回购达789万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1},"content_text":"Ascletis Pharma Inc. disclosed in its Next Day Return (11 June 2026) that it repurchased 200,000 ordinary shares on the Hong Kong Stock Exchange the same day. The shares were bought within a price range of HKD 9.63–10.11, translating into an average cost of HKD 9.83 per share and an aggregate consideration of HKD 1.97 million.\nThe repurchased stock will be cancelled, leaving the company’s share capital structure unchanged ahead of formal cancellation:  \n• Issued shares (excluding treasury shares) remain at 1,061,370,845.  \n• Treasury shares stand at 7,084,210, keeping total issued shares at 1,068,455,055.\nBuy-back mandate utilisation  \n• Ascletis received shareholder approval on 22 May 2025 to repurchase up to 96.28 million shares.  \n• Including the latest transaction, 7.89 million shares have been bought back, equal to 0.82 % of the issued share base on the mandate date.\nRegulatory timeline  \nUnder Hong Kong Listing Rule 10.06(3), the company is subject to a moratorium on issuing new shares or selling treasury shares until 11 July 2026—30 days after the most recent repurchase.\nThe company confirmed all repurchases were executed in compliance with Hong Kong Stock Exchange requirements and that no changes have been made to the explanatory statement lodged on 29 April 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166873089","isCrawlerRequest":true}